Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|March 17, 2023
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIVFelicia L Sterman, Jacob P Lalezari, Ula M Kowalczyk, et al.
Hepatology Communications|February 7, 2018
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infectionNancy Reau, Michael N Robertson, Hwa-Ping Feng, et al.
The Pediatric Infectious Disease Journal|August 29, 2018
Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative InfectionJohn S Bradley, Jocelyn Y Ang, Antonio C Arrieta, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2020
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumoniaLuzelena Caro, David P Nicolau, Jan J De Waele, et al.
International Journal of Antimicrobial Agents|February 10, 2021
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal ClearanceDavid P Nicolau, Jan De Waele, Joseph L Kuti, et al.
Antiviral Therapy|April 8, 2015
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patientsD Hamish Wright, Luzelena Caro, Michael Cerra, et al.
European Journal of Clinical Pharmacology|January 26, 2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairmentLuzelena Caro, Larissa Wenning, Hwa-Ping Feng, et al.
Clinical and Translational Gastroenterology|April 3, 2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT StudyIra M Jacobson, Fred Poordad, Roberto Firpi-Morell, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult ParticipantsHwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.
Pharmacogenomics|June 29, 2019
The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevirZifang Guo, Luzelena Caro, Michael N Robertson, et al.
Pageof 6